In 2023 the Company detailed its approach to maintaining continuity and adaptability under external and internal pressures by closely monitoring the results of its discovery, research, clinical trials and nonclinical studies and frequently evaluating its product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential, resulting in rapid changes in focus and priorities as new information becomes available and competitive dynamics evolve. It leverages a global network of third parties alongside internal capabilities to manufacture and distribute approved products and pipeline candidates, builds and maintains supply chain and quality assurance resources, adapts existing supply chains to include additional formulations or increase production scale, and focuses on ensuring the stability of supply chains for cell and genetic therapies that require specialized systems, equipment, facilities and expertise. The Companyâ€™s cystic fibrosis strategy emphasizes developing and obtaining reimbursement and label expansions, expanding access through early access programs and government and commercial payors, and dedicates substantial management and other resources to secure and maintain appropriate levels of reimbursement in the U.S. and ex-U.S. markets. Capital management practices include forecasting cash flows from product sales, managing liquidity through cash, cash equivalents and marketable securities, maintaining undrawn credit facilities, and dynamically managing the capital structure to support research, development, commercialization and strategic acquisitions and collaborations, thereby enabling the Company to absorb strain, preserve functioning under variability, and position itself to respond effectively to environmental disruptions and emerge stronger from challenging conditions.